Findings from the ACCORD and MPACT study established FOLFIRINOX and the combination of gemcitabine and nab-paclitaxel (Abraxane) as frontline standards of care in metastatic pancreatic cancer, respectively. However, apart from the alterative dosing and scheduling strategies that had been evaluated, limited progress had been made for the better part of the following decade, explained Wang-Gillam. Read more . . .
Although chemotherapy remains the cornerstone of treatment in pancreatic ductal adenocarcinoma, the field has begun to carve out more personalized approaches evidenced by the POLO trial, said Andrea Wang-Gillam, MD, PhD, who emphasized the importance of recommending patients for clinical trials whenever possible to continue moving the needle forward.